within Pharmacolibrary.Drugs.ATC.R;

model R03DA05_2
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.0006666666666666666,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 1200
  );

  annotation(Documentation(
    info ="<html><body><p>Aminophylline is a bronchodilator consisting of theophylline and ethylenediamine, used in the management of asthma, COPD, and sometimes apnea of prematurity. It is administered orally or intravenously, though use has declined in favor of newer drugs.</p><h4>Pharmacokinetics</h4><p>PK parameters estimated for oral administration in adults; limited direct PK data for aminophylline, estimates are drawn from theophylline oral PK.</p><h4>References</h4><ol><li><p>Yin, B, et al., &amp; Wan, RZ (2016). Studies on pharmacokinetics and bioavailability of aminophylline in partridge chickens. <i>European journal of drug metabolism and pharmacokinetics</i> 41(1) 19–25. DOI:<a href=&quot;https://doi.org/10.1007/s13318-014-0225-6&quot;>10.1007/s13318-014-0225-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25323694/&quot;>https://pubmed.ncbi.nlm.nih.gov/25323694</a></p></li><li><p>Aslaksen, A, et al., &amp; Vigander, T (1981). Comparative pharmacokinetics of theophylline and aminophylline in man. <i>British journal of clinical pharmacology</i> 11(3) 269–273. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1981.tb00533.x&quot;>10.1111/j.1365-2125.1981.tb00533.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7213528/&quot;>https://pubmed.ncbi.nlm.nih.gov/7213528</a></p></li><li><p>Choi, HD, et al., &amp; Lee, MG (2007). Effects of water deprivation on the pharmacokinetics of theophylline and one of its metabolites, 1,3-dimethyluric acid, after intravenous and oral administration of aminophylline to rats. <i>Biopharmaceutics &amp; drug disposition</i> 28(8) 445–454. DOI:<a href=&quot;https://doi.org/10.1002/bdd.573&quot;>10.1002/bdd.573</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17847127/&quot;>https://pubmed.ncbi.nlm.nih.gov/17847127</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03DA05_2;
